Circulating Levels of Calprotectin As a Biomarker in Patients With Coronary Artery Disease: A Systematic Review and Meta-Analysis

Overview

Journal Clin Cardiol

Specialty Cardiology & Vascular Diseases

Date 2024 Jul 4

PMID 38961752

Authors

Tara Reshadmanesh

Amir Hossein Behnoush

Maedeh Farajollahi

Amirmohammad Khalaji

Elina Ghondaghsaz

Hassan Ahangar

Affiliations

Soon will be listed here.

Abstract

Background: Calprotectin, also known as MRP8/14, is generated by immune cells and is altered in several inflammatory diseases. Studies have assessed their levels in patients with coronary artery disease (CAD) and its subtypes (stable CAD and acute coronary syndrome [ACS]). Herein, we aimed to systematically investigate these associations through a systematic review and meta-analysis.

Methods: A systematic search was conducted in four online databases, including PubMed, Scopus, Embase, and the Web of Science. Relevant studies were retrieved, screened, and extracted. Random-effect meta-analysis was performed for the calculation of standardized mean difference (SMD) and 95% confidence interval (CI). Blood calprotectin levels were compared between CAD patients and controls, as well as CAD subtypes.

Results: A total of 20 studies were included in the systematic review and meta-analysis, comprising 3300 CAD patients and 1230 controls. Patients with CAD had significantly higher calprotectin levels (SMD 0.81, 95% CI 0.32-1.30, p < 0.01). Similarly, patients with ACS were reported to have higher levels compared to those with stable CAD. However, there was no significant difference in terms of blood calprotectin levels between stable CAD cases and healthy controls. Finally, studies have shown that calprotectin could be used as a diagnostic biomarker of CAD while also predicting major adverse events and mortality in these patients.

Conclusion: Based on our findings, calprotectin, as an inflammatory marker, could be used as a possible biomarker for patients with CAD and ACS. These suggest the possibility of pathophysiological pathways for this involvement and warrant further research on these associations as well as their clinical utility.

References

Jensen L, Pedersen S, Bjerre M, Mogelvang R, Skov Jensen J, Flyvbjerg A . Plasma calprotectin predicts mortality in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention. J Interv Cardiol. 2010; 23(2):123-9. DOI: 10.1111/j.1540-8183.2010.00532.x. View

Naess-Andresen C, Egelandsdal B, Fagerhol M . Calcium binding and concomitant changes in the structure and heat stability of calprotectin (L1 protein). Clin Mol Pathol. 1995; 48(5):M278-84. PMC: 407985. DOI: 10.1136/mp.48.5.m278. View

Liu Y, Guan S, Xu H, Zhang N, Huang M, Liu Z . Inflammation biomarkers are associated with the incidence of cardiovascular disease: a meta-analysis. Front Cardiovasc Med. 2023; 10:1175174. PMC: 10360053. DOI: 10.3389/fcvm.2023.1175174. View

Noohi Bezanjani F, Gohari S, Bassiri H, Ahangar H, Reshadmanesh T . Risk Factors Associated with Heart Valve Thrombosis in Patients with Prosthetic Heart Valve Dysfunction. Arch Iran Med. 2020; 23(9):600-604. DOI: 10.34172/aim.2020.70. View

Miyamoto S, Ueda M, Ikemoto M, Naruko T, Itoh A, Tamaki S . Increased serum levels and expression of S100A8/A9 complex in infiltrated neutrophils in atherosclerotic plaque of unstable angina. Heart. 2008; 94(8):1002-7. DOI: 10.1136/hrt.2007.121640. View

Altwegg L, Neidhart M, Hersberger M, Muller S, Eberli F, Corti R . Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes. Eur Heart J. 2007; 28(8):941-8. DOI: 10.1093/eurheartj/ehm078. View

Egger M, Davey Smith G, Schneider M, Minder C . Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-34. PMC: 2127453. DOI: 10.1136/bmj.315.7109.629. View

Steg P, Ducrocq G . Future of the Prevention and Treatment of Coronary Artery Disease. Circ J. 2016; 80(5):1067-72. DOI: 10.1253/circj.CJ-16-0266. View

Bouma G, Lam-Tse W, Wierenga-Wolf A, Drexhage H, Versnel M . Increased serum levels of MRP-8/14 in type 1 diabetes induce an increased expression of CD11b and an enhanced adhesion of circulating monocytes to fibronectin. Diabetes. 2004; 53(8):1979-86. DOI: 10.2337/diabetes.53.8.1979. View

10.

Marinkovic G, Grauen Larsen H, Yndigegn T, Szabo I, Mares R, de Camp L . Inhibition of pro-inflammatory myeloid cell responses by short-term S100A9 blockade improves cardiac function after myocardial infarction. Eur Heart J. 2019; 40(32):2713-2723. DOI: 10.1093/eurheartj/ehz461. View

11.

Viemann D, Barczyk K, Vogl T, Fischer U, Sunderkotter C, Schulze-Osthoff K . MRP8/MRP14 impairs endothelial integrity and induces a caspase-dependent and -independent cell death program. Blood. 2006; 109(6):2453-60. DOI: 10.1182/blood-2006-08-040444. View

12.

McCormick M, Rahimi F, Bobryshev Y, Gaus K, Zreiqat H, Cai H . S100A8 and S100A9 in human arterial wall. Implications for atherogenesis. J Biol Chem. 2005; 280(50):41521-9. DOI: 10.1074/jbc.M509442200. View

13.

Ehlermann P, Eggers K, Bierhaus A, Most P, Weichenhan D, Greten J . Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. Cardiovasc Diabetol. 2006; 5:6. PMC: 1475836. DOI: 10.1186/1475-2840-5-6. View

14.

Vora A, Bonaca M, Ruff C, Jarolim P, Murphy S, Croce K . Diagnostic evaluation of the MRP-8/14 for the emergency assessment of chest pain. J Thromb Thrombolysis. 2012; 34(2):229-34. PMC: 4113032. DOI: 10.1007/s11239-012-0705-y. View

15.

Song N, Zhen X, Li L, Zhong L, Wang H, An Y . Plasma calprotectin was associated with platelet activation and no-reflow phenomenon in acute coronary syndrome. BMC Cardiovasc Disord. 2020; 20(1):443. PMC: 7547482. DOI: 10.1186/s12872-020-01717-5. View

16.

Morrow D, Wang Y, Croce K, Sakuma M, Sabatine M, Gao H . Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22).... Am Heart J. 2007; 155(1):49-55. PMC: 2645040. DOI: 10.1016/j.ahj.2007.08.018. View

17.

Larsen S, Grove E, Pareek M, Kristensen S, Hvas A . Calprotectin and platelet aggregation in patients with stable coronary artery disease. PLoS One. 2015; 10(5):e0125992. PMC: 4430524. DOI: 10.1371/journal.pone.0125992. View

18.

Vogl T, Ludwig S, Goebeler M, Strey A, Thorey I, Reichelt R . MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. Blood. 2004; 104(13):4260-8. DOI: 10.1182/blood-2004-02-0446. View

19.

Santilli F, Paloscia L, Liani R, Di Nicola M, Di Marco M, Lattanzio S . Circulating myeloid-related protein-8/14 is related to thromboxane-dependent platelet activation in patients with acute coronary syndrome, with and without ongoing low-dose aspirin treatment. J Am Heart Assoc. 2014; 3(4). PMC: 4310373. DOI: 10.1161/JAHA.114.000903. View

20.

Robinson M, Tessier P, Poulsom R, Hogg N . The S100 family heterodimer, MRP-8/14, binds with high affinity to heparin and heparan sulfate glycosaminoglycans on endothelial cells. J Biol Chem. 2001; 277(5):3658-65. DOI: 10.1074/jbc.M102950200. View